City of Hope has so many breakthroughs in cancer, diabetes and HIV/AIDS - and so many stories - that we've tailored our blog, Breakthroughs, to provide something for every reader. Whether the breakthroughs are about medical research, treatment advances or personal triumphs, they're all connected.
September 22, 2017 | Katie Neith
The Ivy Foundation aims to cure brain cancer by funding innovative research that will improve diagnostics and treatment options. It recently awarded sizable grants to two City of Hope researchers.
July 24, 2017 | Denise Heady
A study led by City of Hope neurosurgeon and scientist Rahul Jandial, M.D., Ph.D., offers novel insights on how cancer cells in HER2-positive breast cancer develop the ability to break through the blood-brain barrier and, ultimately, how they can be stopped.
July 10, 2017 | Stephanie Smith
When viewed under a microscope, T cells - sentinels of the immune system whose job inside the body is to seek out foreign invaders - quiver as they surround and consume cancer cells. They were genetically modified in a lab by City of Hope researchers and trained to target specific receptors on patients’ brain tumors - part of an emerging approach to cancer care called immunotherapy.
January 4, 2017 | Stephanie Smith
Sketches of a brain surgery performed on B., one of several patients in a breakthrough clinical trial for brain cancer at City of Hope. Early results of the trial — describing promising results using CAR-T cells for a 50-year-old patient with an aggressive brain cancer called glioblastoma multiforme — were published recently in the New England Journal of Medicine.
December 28, 2015 | Denise Heady
Patients have long needed a better treatment option for brain tumors. As we enter 2016, just such an option is taking shape: CAR-T cell therapy.
October 26, 2015 | City of Hope
Brain cancer is one of the toughest foes a doctor can face. It’s a tenacious form of cancer, inoperable in some cases and lethal in many. But at City of Hope, researchers are exploring new ways to conquer the most serious types of brain tumors in a clinical trial that deploys a patient’s own modified T cells to target cancer at the tumor site.